Rovalpituzumab Biosimilar, DLL3 Monoclonal Antibody

Additional Information:
C108P: Rovalpituzumab Biosimilar, DLL3 Monoclonal AntibodyRecombinant Humanized IgG1 Monoclonal Antibody.|Isotype: Human IgG1 kap|The anti-human DLL3 monoclonal antibody rovalpituzumab biosimilar was produced in mammal cells.|Specificity/Sensitivity: The in vivo grade rovalpituzumab biosimilar specifically binds to the human DLL3 protein.|Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.|Endotoxin: |Purity: >95% by SDS-|The research grade rovalpituzumab biosimilar is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70°C as supplied.1 month from date of receipt, 2 to 8°C as supplied.|BackgroundWhat is rovalpituzumab biosimilar research grade? Rovalpituzumab is a humanized IgG1-kappa monoclonal antibody against the human Delta-like 3 protein (DLL3), which is an atypical Notch ligand that has been implicated in regulation of cell development and cell fate decisions, and is a downstream target of achaetescute homolog-1 (ASCL1), suggesting its role in neuroendocrine tumorigenesis. DLL3 is expressed in more than 80% of patients with small-cell lung cancer (SCLC) and other neuroendocrine tumors, but has little to no expression in normal tissues or non-neuroendocrine tumor types. DLL3 expression appears to be stable over time in SCLC tumors pre- and post-chemotherapy. Although DLL3 is mostly found within the Golgi apparatus under physiological conditions, it may reach the cell surface in case of overexpression and lead to Notch inhibition in cis. Rovalpituzumab tesirine (Rova-T) is a first-in-class antibody–drug conjugate (ADC) against DLL3, and composed of SC16, a humanized IgG1 antibody against DLL3, conjugated to the cytotoxic pyrrolobenzod (PBD) dimer D6.5 (SC-DR002) v a protease-cleavable linker. Rova-T selectively binds to DLL3 on target-expressing cells, is internalized, and upon proteolytic cleavage releases the toxin. PBD dimers then bind to the DNA minor groove where they form covalent adducts causing stalling of the replication forks, cell-cycle arrest at the G2–M boundary, and apoptosis. Rovalpituzumab biosimilar uses the same protein sequences as the therapeutic antibody rovalpituzumab.Syd Labs provides the following research grade antibody biosimilars used in ADCs:Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibodyRovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibodyTrastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibodyCofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibodyIfinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibodySacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibodyGemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibodyPolatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibodyCetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody